Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore, a new clinically validated precision medicine tool to enhance its myRisk Hereditary Cancer test. riskScore quantifies a woman's risk of developing breast cancer by combining genetic markers throughout the genome with her family and clinical history.
More...